Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies
Michael P. Rettig, Jan Davidson‐Moncada(MacroGenics (United States)), Daner Li(MacroGenics (United States)), Daniel Primo, Paul A. Moore(Zymeworks (Canada)), Jan Baughman(University of California System), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Norbert Vey(Centre de Recherche en Cancérologie de Marseille), John E. Godwin(Providence Portland Medical Center), Carmen Ballesteros‐Merino(Cancer Institute (WIA)), Carlo Bifulco(Providence Health & Services), John F. DiPersio(Washington University in St. Louis), Bernard A. Fox(Oregon Health & Science University), John Muth(MacroGenics (United States)), Ross La Motte‐Mohs(MacroGenics (United States)), Jichao Sun(MacroGenics (United States)), Joan Ballesteros, Hélène Lelièvre(Domain Therapeutics (France)), Ezio Bonvini(MacroGenics (United States))
Cited by 12
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k